Robert Doebele - 07 Jan 2022 Form 4 Insider Report for Rain Therapeutics Inc.

Reporting relationship: EVP, Chief Scientific Officer
Issuer ticker: N/A
Reported as of: 07 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Feb 2022, 15:35:13 UTC
Next SEC filing: 04 Apr 2022
Source filing: View source filing
Reporting owner signature: /s/ Nelson Cabatuan, Attorney-in-fact for Robert Doebele

Key filing fact

Robert Doebele filed Form 4 for Rain Therapeutics Inc. on 04 Feb 2022.

Key facts

This page summarizes Robert Doebele's Form 4 filing for Rain Therapeutics Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Feb 2022, 15:35.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RAIN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +72,000
Change %
Price: $0.000000
Shares after: 72,000
Date: 07 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 72,000
Exercise price: $12.01
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option represents a right to purchase a total of 72,000 shares of the Issuer's common stock, one quarter of which will vest on January 7, 2023, with the remaining three quarters vesting in equal monthly installments through January 7, 2026, subject to the Reporting Person's continued service to the Issuer.